Therefore modulation of TLR2 activation may be of limited therapeutic benefit during chronic intestinal inflammation and future studies should focus on alternative PRR pathways that may play a non-redundant role in IBD pathogenesis. The gene discussed is TLR2; the disease is inflammatory bowel disease.